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The major allergen, Cry j 1, was isolated from Japanese cedar Cryptomeria japonica (Cry j) pollen and was
shown to react with immunoglobulin E antibodies in the sera from pollinosis patients. We previously reported
that the frequency of HLA-DP5 was significantly higher in pollinosis patients and the immunodominant
peptides from Cry j 1 bound to HLA-DP5 to activate Th2 cells. In the present study, we determined the crystal
structure of the HLA-DP5 heterodimer in complex with a Cry j 1-derived nine-residue peptide, at 2.4 Å
resolution. The peptide-binding groove recognizes the minimal peptide with 10 hydrogen bonds, including
those between the negatively charged P1 pocket and the Lys side chain at the first position in the peptide
sequence. We confirmed that HLA-DP5 exhibits the same Cry j 1-binding mode in solution, through pull-down
experiments using structure-based mutations of Cry j 1. We also identified the characteristic residues of
HLA-DP5 that are responsible for the distinct properties of the groove, by comparing the structure of HLA-DP5
and the previously reported structures of HLA-DP2 in complexes with pDRA of the self-antigen. The
comparison revealed that the HLA-DP5·pCry j 1 complex forms several hydrogen bond/salt bridge networks
between the receptor and the antigen that were not observed in the HLA-DP2·pDRA complex. Evolutionary
considerations have led us to conclude that HLA-DP5 and HLA-DP2 represent two major groups of the
HLA-DP family, in which the properties of the P1 and P4 pockets have evolved and acquired the present
ranges of epitope peptide-binding specificities.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Plant pollens are the most common causes of
prevalent type I hypersensitivity (allergy) diseases,uthors. Published by Elsevier Ltd. This
rg/licenses/by-nc-nd/3.0/).which induce seasonal rhinitis and conjunctivitis in
humans [1–3]. Dactylis gromerata and Ambrosia
artemisiifolia (ragweed) pollens cause the two major
hay fevers endured internat ional ly, whi leis an open access article under the CC BY-NC-ND license
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3017Crystal Structure of the HLA-DP5•Cry j 1 Complex.Cryptomeria japonica (Cry j, Japanese cedar) pollen
is the most prevalent allergen in Japan [4], with
respect to the number of pollinosis patients. In
particular, the number of Japanese cedar pollinosis
patients has rapidly increased since the 1960s in
Japan [5], and presently, more than 25million people
suffer through the months from February to April,
when the pollen is dispersed [6]. So far, three major
allergens, Cry j 1 [7], Cry j 2 [8], and Cry j 3 [9], have
been isolated from the cedar pollen and have been
shown to react with immunoglobulin E (IgE) anti-
bodies from the pollinosis patients [9,10]. Cry j 1 and
Cry j 2 are 37–45 kDa basic glycoproteins [11], and
they share 70–80% amino acid sequence identity
with each other [11]. They were identified as a
pectate lyase (isozyme) [12] and a polymethylga-
lacturonase (enzyme) [13], respectively.
IgE is responsible for inducing type I hypersensitivity
(allergic) diseases [14]. Secretion of antibodies, includ-
ing IgE, by plasma cells requires interactions between
antigen-activated B cells and antigen-activated CD4+
type 2 helper T (Th2) cells, to allow the differentiation of
plasma cells fromB cells. CD4+ T cells are activated by
the recognition of immunogenic peptides presented by
class II human leukocyte antigen (HLA) molecules on
the surface of antigen-presenting cells [15]. The
allergen-specific IgE production completely depends
on the class switch of the immunoglobulin gene in
plasma cells, and this is mediated by a cytokine,
interleukin-4, produced by CD4+ Th2 cells upon the
recognition of allergen-derived peptides in the context
of class II HLA molecules.
The class II HLA molecules are heterodimers of the
α and β chains and are encoded by genes in the class
II HLA region on the short arm of chromosome 6 [16].
The class II HLA molecules are classified into three
isotypes, HLA-DR, HLA-DQ, and HLA-DP. In
HLA-DR, the polymorphic variation is primarily pro-
vided by the β chain, rather than the α chain [17]. On
the other hand, in HLA-DQ and HLA-DP, both the α
and β chains are polymorphic, and thus, a variety of
HLA-DQA/DQB and HLA-DPA/DPB haplotypes are
formed [17]. The crystal structures of class II HLA
complexeswith non-self-peptides derived fromaplant
have been determined for the HLA-DQ2·deamida-
ted-gliadin [18], the HLA-DQ2.3·Gamma-gliadin [19],
and the HLA-DQ8·deamidated-glutein [20,21]. Nine
specific amino acid residues in each peptide are
accommodated in the peptide-binding groove, formed
by the α and β chains.
We previously analyzed the statistical association
between Japanese cedar pollinosis and class II HLA
alleles and found that the patients possess the
HLA-DP5 (DPA1*02:02 and DPB1*05:01) at a rate
of about 80% [22]. Furthermore, we also identified an
immunodominant peptide that induces HLA-D-
P5-restricted Th2 cells, among 38 synthesized
overlapping 13-residue peptides spanning the entire
length of Cry j 1. The minimal peptide sequence forthe HLA-DP5-restricted Th cells was suggested to
be nine residues, 214-KVTVAFNQF-222, of Cry j 1
[22]. Therefore, we thought that the HLA-DP5-asso-
ciated susceptibility to Japanese cedar pollinosis
may be explained by the following phenomenon:
HLA-DP5-mediated antigen presentation of the
major Cry j 1 epitope to Th2 cells producing
interleukin-4, an essential cytokine for IgE produc-
tion by antibody-secreting plasma cells. Subse-
quently, it was reported that a large number of Cry
j 1 and Cry j 2 peptides were associated with various
class II HLA allelic products. Among the HLA-DP
family members, only HLA-DP5 and HLA-DP2 were
shown to be associated with the Cry j antigenic
peptides [23,24]. However, the structural mecha-
nisms of specific peptide recognition are still
unknown, for not only the peptides of the Cry j
antigens but also those of other pollen antigens. The
only peptide-bound HLA-DP structure available is
that of HLA-DP2 (DPA1*01:03 and DPB1*02:01) in
complex with pDRA derived from the self-HLA-DR α
chain [25].
In the present study, we determined the crystal
structure of the extracellular region of the HLA-DP5
(DPA1*02:02 and DPB1*05:01) heterodimer, in com-
plex with the Cry j 1-derived nine-residue peptide,
KVTVAFNQF, at 2.4 Å resolution. The peptide-bind-
ing groove specifically formed by the HLA-DP5α and
HLA-DP5β chains captures the minimal peptide
KVTVAFNQF with 10 hydrogen bonds, including
those between the negatively charged P1 pocket
and the Lys side chain at the first anchoring position in
the peptide sequence. This binding mode was
confirmed in vitro, by mutations of the Cry j 1 residues
facing the peptide-binding groove of HLA-DP5 in the
crystal structure. Furthermore, we identified the
characteristic residues of HLA-DP5 that are respon-
sible for the distinct properties of the groove, by
comparing the structure of HLA-DP5 and the previ-
ously reported structure of HLA-DP2 (DPA1*01:03
and DPB1*02:01) in complex with pDRA. The
comparison revealed that the HLA-DP5·Cry j 1
complex forms several hydrogen bond/salt bridge
networks between the receptor and the antigen that
were not observed in the HLA-DP2·pDRA complex.
Thus, the specific HLA-DP–antigenic peptide binding
mechanism has been established.Results
Overall structure of the complex of HLA-DP5
with the Cry j 1 peptide
We prepared a plasmid encoding the HLA-DP5 α
chain extracellular region (residues 1–181) and the
HLA-DP5 β chain extracellular region (residues 4–189)
with the N-terminus fused to a nine-amino-acid residue
Table 1. Crystallographic data collection and refinement
statistics
HLA-DP5·Cry j 1(9-mer)
Data collection
Space group P1
Cell dimensions
a, b, c (Å) 61.2, 64.4, 130.4
α, β, γ (°) 93.0, 97.5, 109.4
Resolution (Å) 64–2.4 (2.49–2.40)a,b
Rsym 0.116 (0.563)
I/σI 12.3 (3.05)
Completeness (%) 97.4 (95.6)
Redundancy 3.5 (3.4)
Refinement
Resolution (Å) 64.0–2.4
No. of reflections 70,445
Rwork/Rfree 0.201/0.237
No. of atoms
Protein 12,380
Ligand 56
Water 267
B-factors
Protein 29.1
Ligand 27.6
Water 29.8
rmsd
Bond lengths (Å) 0.005
Bond angles (°) 1.07
a One crystal was used for data collection and refinement.
b Values in parentheses are for the highest-resolution shell.
3018 Crystal Structure of the HLA-DP5•Cry j 1 Complex.Cry j 1 peptide (KVTVAFNQF) and co-expressed the
two chains by the baculovirus–insect cell expression
system. It was assumed that the α and β chains ofFig. 1. Crystal structure of the HLA-DP5·Cry j 1 complex.
Extracellular domains of the HLA-DP5α and HLA-DP5β chains
(α2) and in blue (β1) and light blue (β2), respectively. The C
Overall structure. (b) Top views of the peptides in the pepti
peptide-binding groove. The 2Fo − Fc electron density maps
refinement) and an olive mesh (after refinement) within 1.0 Å o
HLA-DP5·Cry j 1(9-mer) complex. (d) Distribution of sedimenta
(e) A plot of the sedimentation equilibrium data with the residuHLA-DP5 form a “heterodimer” and that the peptide
fused to the β chain is accommodated in the binding
site formed by the two chains. The HLA-DP5·Cry j
1(9-mer) complex was purified and crystallized as
described in Materials and Methods, and the structure
was determined at 2.4 Å resolution. The statistics for
the data collection and the refined model is shown in
Table 1. The asymmetric unit of the HLA-DP5·Cry j
1(9-mer) crystal contains four complexes, A, B, C, and
D. Each complex superposed on another with a
root-mean-square deviation (rmsd) value of ~0.8 Å
for the Cα atoms. Therefore, the structure of complex A
is describedhereafter. Theαandβ chains consist of the
α1 and α2 domains and the β1 and β2 domains,
respectively (Fig. 1a). The α1 and β1 domains form the
peptide-binding cleft, and the α2 and β2 domains form
the heterodimeric interface (Fig. 1a andb). AnN-acetyl-
D-glucosamine moiety is attached to Asn118 (α2
domain) in HLA-DP5·Cry j 1(9-mer) (Fig. 1a). The
overall structures of the HLA-DP5 heterodimers are
similar to those of the class II HLA heterodimers [26],
including HLA-DP2.
In the HLA-DP5·Cry j 1(9-mer) structure, the nine
residues of the accommodated Cry j 1 peptide
(KVTVAFNQF) are clearly visible in the electron
density map and occupy the p1-to-p9 binding
pockets (Fig. 1b and c). Lys(p1), Phe(p6), and
Phe(p9) are the “anchoring residues”, and their
side chains are buried within their corresponding
pockets formed along the peptide-binding groove of
HLA-DP5 (Fig. 1c). In solution, the purified
HLA-DP5·Cry j 1(9-mer) complex exists as a single(a–c) The HLA-DP5·Cry j 1(214–222) complex structure.
are shown as ribbon models in green (α1) and light green
ry j 1(9-mer) peptide is represented by orange sticks. (a)
de-binding groove. (c) Side views of the peptides in the
, contoured at 1.5σ, are shown as a cyan mesh (before
f the peptide. (d and e) Analytical ultracentrifugation of the
tion coefficients (s) by sedimentation velocity experiments.
als from the best fit to a single ideal species.
3019Crystal Structure of the HLA-DP5•Cry j 1 Complex.complex species, as revealed by analytical ultracen-
trifugation (Fig. 1d and e).
Binding mode of HLA-DP5·Cry j 1(9-mer)
The Cry j 1 peptide interacts extensively with the
side chains from the HLA-DP5 groove, involving a
total of 10 hydrogen bonds, with four formed by the
p1, p7, and p8 side chains and six mediated by the
p2, p4, p5, and p7 main chains of the peptide
(Fig. 2a). Actually, in common mostly with the
peptide·HLA-DR1 complexes, five hydrogen bonds
are observed between the main chain of the Cry j 1
peptide and the side chains of HLA-DP5: p2 and
Tyr9(α), p2 and Asn80(β), p4 and Asn62(α), p5 and
Lys69(β), and p7 and Asn69(α). Moreover, the otherfive hydrogen bonds are formed between the side
chains of the peptide and HLA-DP5. This binding by
an extensive hydrogen bonding network is in sharp
contrast to the binding of the pDRA peptide with
HLA-DP2 [25] (PDB ID: 3LQZ), which involves
mostly hydrophobic interactions with only one
hydrogen bond (Fig. 2b). A unique feature of the
HLA-DP5·Cry j 1 peptide interactions is that the side
chain of one of the anchoring residues, Lys(p1),
hydrogen bonds with Gln31α and Asp84β (Fig. 2d).
The main chain, but not the side chain, of Val(p2)
hydrogen bonds with Tyr9α and Asn80β (Fig. 2d).
On the other hand, the side chain of Thr(p3) forms
hydrophobic interactions with Phe22α and Phe54α
(Fig. 2e). The side chain of Val(p4) also forms
hydrophobic interactions with Phe24β, Val72β, and
Met76β, while the main chain hydrogen bonds with
Asn62α and Gln13β (Fig. 2e). The main chain of
Ala(p5) hydrogen bonds with Lys69β (Fig. 2e). The
side chain of another anchoring residue, Phe(p6),
interacts hydrophobically with Met11α, Leu66α, and
Tyr26β (Fig. 2e). The side and main chains of
Asn(p7) hydrogen bond with Tyr28β and Asn69α,
respectively (Fig. 2f). The side chain of Gln(p8)
hydrogen bonds with Asn68α (Fig. 2f). Finally, the
side chain of Phe(p9) forms hydrophobic interactions
with Leu73α, Phe9β, Leu35β, Val36β, and Trp59β
(Fig. 2f). In addition, the side chains of Val(p2),
Thr(p3), and Val(p4) do not fill their corresponding
pockets, indicating that some larger side chains
might be accommodated in these pockets (Fig. 2c).Fig. 2. Binding mode of the HLA-DP5·Cry j 1(9-mer)
complex. (a) The hydrogen bonds between HLA-DP5 and
the Cry j 1(9-mer) peptide. The residues of HLA-DP5α and
HLA-DP5β involved in direct hydrogen bonding are
labeled in green and blue circles, respectively. The Cry j
1(9-mer) peptide is shown as an orange stick model. (b)
The hydrogen bond between HLA-DP2 and the pDRA
peptide (PDB ID: 3LQZ). The pDRA peptide is shown as a
purple stick model. The residue of HLA-DP2α involved in
direct hydrogen bonding is labeled in the purple circle. (c)
Top view of the Cry j 1(9-mer) peptide and the nine pockets
in the peptide-binding groove. HLA-DP5α and HLA-DP5β
are shown in green and blue surface presentations,
respectively. The Cry j 1(9-mer) peptide is depicted by
an orange stick model. Details of the Cry j 1(p1–p2) (d),
Cry j 1(p3–p6) (e), and Cry j 1(p7–p9) (f) interactions in the
peptide-binding groove of HLA-DP5 are shown. (a–e) The
hydrogen bonds are represented as broken lines. (g)
Mutant analysis based on the HLA-DP5·Cry j 1(9-mer)
complex. HLA-DP5 was prepared by co-expressing
HLA-DP5α and the Cry j 1–HLA-DP5β fusion protein in
the cell-free synthesis system. Interactions of the Cry j
1(9-mer) mutants with HLA-DP5 were analyzed: His-tagged
HLA-DP5αwascapturedandstainedwithCoomassieBrilliant
Blue (top panel), and FLAG-tagged Cry j 1–HLA-DP5β was
immunoprecipitatedanddetectedbyWestern blotting (bottom
panel). Representative data from three independent experi-
ments are presented.
Fig. 3. Comparison of the HLA-DP5·Cry j 1(9-mer) complex with the HLA-DP2·pDRA complex. (a and b) Electrostatic
potential maps of HLA-DP5 (a) and HLA-DP2 (b). Positive potential, blue; negative potential, red. The positions of the P1–
P9 pockets for the Cry j 1 and pDRA peptides are indicated. (c) Superimposition of the HLA-DP5·Cry j 1(9-mer) complex
on the HLA-DP2·pDRA complex. The major structural difference in the backbones of the peptides is indicated with a
broken circle (Site 1). (d–h) Close-up views in stick presentations. Details of the Site 1 (d) and P1 (e), P4 (f), P7 (g), and P9
(h) pockets are shown. (c–h) The peptides and HLA molecules are colored orange (Cry j 1), purple (pDRA), green
(HLA-DP5α), blue (HLA-DP5β), white (HLA-DP2α), and gray (HLA-DP2β), respectively. (i) According to Ref. [25], we
compared the published human and mouse major histocompatibility complex II structures with a bound peptide with the
total width of the peptide-binding groove (D1), the size of the gap between the peptide and the β chain α helix (D2), and the
distance between the peptide and the floor of the binding groove (D3). (j) Non-conserved residues of the peptide-binding
grooves between HLA-DP5 and HLA-DP2 are shown in yellow. The residues of HLA-DP5α and HLA-DP5β are labeled in
green and blue, respectively, and those of HLA-DP2 are shown in parentheses.
3020 Crystal Structure of the HLA-DP5•Cry j 1 Complex.To examine the contributions of the Cry j 1 side
chains to the binding with HLA-DP5α and/or
HLA-DP5β, we created five mutants of the Cry j 1
9-mer peptide (Fig. 2g). In this study, HLA-DP5 was
prepared by co-expressing HLA-DP5α and the Cry j
1–HLA-DP5β fusion protein in the cell-free synthesis
system, since the HLA-DP5α·HLA-DP5β heterodi-mer was not formed by the co-expression of
HLA-DP5α and HLA-DP5β without the Cry j 1 fusion.
Using this property, we analyzed the interactions of
the Cry j 1 9-mer mutants with HLA-DP5: His-tagged
HLA-DP5α was captured, and the level of HLA-D-
P5α·Cry j 1–HLA-DP5β complex formation was
monitored by the amount of co-precipitated Cry j 1–
Fig. 4. Phylogenetic analyses of the HLA-DP alleles. (a)
Phylogenetic tree of the HLA-DPA1 alleles. (b) Phyloge-
netic tree of the HLA-DPB1 alleles. (a and b) The NJ tree
was constructed with only synonymous substitutions. Only
the amino acid substitutions that occurred in the PBR were
parsimoniously inferred and placed on or under each
branch. For simplicity, not all amino acid substitutions on
the main branches are shown. Particularly, position 55, 65,
or 69 of the DPβ chain is not listed in each branch because
of high-frequency replacement. For DPA1, the ancestral
state was determined by a comparison with HLA-DRA.
However, no appropriate outgroup sequence was found
for DPB1, and the ancestral state was inferred from the
extant sequences. Green characters represent substitu-
tions in the PBR. Blue and orange characters indicate
residues of HLA-DP2 and HLA-DP5, respectively.
3021Crystal Structure of the HLA-DP5•Cry j 1 Complex.HLA-DP5β. Mutations at the p1, p7, and p9 positions of
the Cry j 1 peptide reduced the level of HLA-DP5α·H-
LA-DP5β complex formation (Fig. 2g). The effects of
the p1 and p7 mutations were quite drastic. Lys(p1) is
bound in the deep acidic pocket involving Gln31α andAsp84β, and its mutation to Glu (Kp1E) caused
repulsion within the pocket (Fig. 2d). The mutation of
Asn(p7) to the longer Gln (Np7Q) may have impaired
the hydrogen bonding with Tyr28β (Fig. 2f). The
mutation of Phe(p9) to Ala (Fp9A) probably weakened
the hydrophobic interaction with the p9 pocket (Fig. 2f).
In contrast, the Tp3Y and Np8E mutations exhibited
negligible effects on the level of complex formation
(Fig. 2g). Actually, the Tyr substitution for Thr(p3) may
be accommodated well in the pocket constituted by
Phe22α and Phe54α (Fig. 2e), while Glu at position p8
may interact with the pocket in the same manner as
Gln(p8) (Fig. 2f).
Properties of the peptide-binding grooves of
HLA-DPs and other class II HLA molecules
The HLA-DP5·Cry j 1 and HLA-DP2·pDRA
complex structures superimposed on each other
almost perfectly, with an rmsd value of 1.0 Å for the
equivalent Cα atoms. In the HLA-DP5 and HLA-DP2
structures, the P1, P4, P6, and P9 pockets are
significantly deeper than the P2, P3, and P7 pockets
(Fig. 3a and b). However, each of the four deeper
pockets of HLA-DP5 has a different position, size, or
charge from that of the corresponding pocket of
HLA-DP2. The bottom of the P1 pocket of HLA-DP5
consists of Gln31α and Asp84β and is negatively
charged (Fig. 3a and e). Therefore, the HLA-DP5 P1
pocket is suitable for accommodating a positively
charged amino acid residue, such as Lys. In
contrast, the bottom of the HLA-DP2 P1 pocket is
hydrophobic (Fig. 3b and e). The acidic P1 pocket is
also present in some class II HLA structures, such as
HLA-DQ2 [18], HLA-DQ2.3 [19], and HLA-DQ8 [20].
On the other hand, the P4 pocket of HLA-DP5 has a
positive charge (Lys69β), whereas that of HLA-DP2
has three negative charges (Glu26β, Glu68β, and
Glu69β) (Fig. 3a and b) [25]. The distance between
the P6 and P9 pockets of HLA-DP5 is shorter than
that of HLA-DP2 (Fig. 3a and b); the Tyr28β side
chain shifts toward the P9 pocket and hydrogen
bonds with Asn(p7)(Cry j 1) (Fig. 3g). Furthermore,
the diameter and the depth of the P9 pocket are larger
in HLA-DP5 than in HLA-DP2 [25] (Fig. 3a and b) due
to the differences between Glu55β(HLA-DP5) and
Asp55β(HLA-DP2) and between Leu35β(HLA-DP5)
and Phe35β(HLA-DP2) (Fig. 3h).
We compared the width of the peptide-binding
groove, represented by the distance between
position 62α in the α1 domain and position 69β in
the β1 domain (Fig. 3i) of HLA-DP5 with those of
HLA-DP2 and other class II major histocompatibility
complex/HLA molecules. The peptide-binding
groove of HLA-DP2 is the widest (16.18 Å) [25]. By
contrast, the groove width of HLA-DP5 is 15.08 Å,
which is close to the average value (15.01 Å) [25] of
the other structures. We also measured the distance
between the peptide and the groove floor, as
Table 2. The non-conserved residues of HLA-DPs that affect the properties of the peptide-binding grooves
HLA–DP Peptide–binding groove
Position 31(α)
Q (P1) (charge)
M (P1)
Position 84(β)
D (P1) (charge)
G (P1)
Position 69(β)
K (P4) (closed)
E (P4) (open)
Position 11(α)
M (P6) (depth)
A (P6)
Position 35(β)
L (P9) (depth)
F (P9)
Position 55(β)
E (P9) (width)
D (P9)
HLA–DP5a
HLA–DP2b
aDPA1*02:02 and DPB1*05:01.
bDPA1*01:03 and DPB1*02:01.
Blue boxes: The position involves divergent residues based on DPA1 and DPB1 four-digit allele-level typing.
Green boxes: The position involves divergent residues identified by comparing the structures of HLA-DP5·Cry j 1 and HLA-DP2·pDRA.
3022 Crystal Structure of the HLA-DP5•Cry j 1 Complex.determined by positions p4 and 13(β) in the β1
domain (Fig. 3i). The distances in the HLA-DP5 and
HLA-DP2 structures are 8.40 Å (the longest) and
8.06 Å, respectively, while the average value in the
other class II major histocompatibility complex/HLA
structures is 6.54 Å [25]. A superimposition of
HLA-DP5 bound with the Cry j 1 peptide onto
HLA-DP2 bound with pDRA (Fig. 3c) revealed that
the position of Phe(p6) of Cry j 1 is shifted up by the
side chain of Met11α, as compared with Phe(p6) of
pDRA. The main chain of Ala(p5) of Cry j 1 is
consequently pushed up (Fig. 3d), which facilitates
its characteristic interaction with Lys69α(HLA-DP5)
(Fig. 3f). The amino acid sequence of HLA-DP5 is
highly homologous to that of HLA-DP2, with a
sequence identity of 95%. Six of the seventeen
non-conserved residues are clustered in the pepti-
de-binding groove: Met11 and Gln31 of the α chain;
Leu35, Glu55, Lys69, and Asp84 of the β chain of
HLA-DP5 (Fig. 3j). It should be emphasized here that
these non-conserved residues participate in the
formation of the P1, P4, P6, and P9 pockets, as
described above, to achieve the distinct specificities
of the peptide binding by HLA between HLA-DP5
and HLA-DP2.
Evolutionary analysis of HLA-DP alleles in the
peptide-binding region
To scrutinize the non-conserved residues between
HLA-DP5 and HLA-DP2, we constructed phyloge-
netic trees based on the synonymous substitutions
under the molecular clock hypothesis (Fig. 4a and b;
Supplementary Fig. 1a). In both the DPA1 and DPB1
trees, the extent of synonymous divergence was
about 4% between HLA-DP2 and HLA-DP5, which
represents divergence 20 million years ago, using a
synonymous substitution rate of 10−9/site/year.
Thus, HLA-DP2 and HLA-DP5 diverged long ago.
Since then, the DPA1 and DPB1 genes have
accumulated further lineage-specific amino acid
substitutions, and each formed the DP2 and DP5
groups with multiple members (Fig. 4a and b;
Supplementary Fig. 1b and c). Especially, theamino acid substitutions involving Met11α and
Gln31α in the peptide-binding region (PBR) of the
DP5 group occurred twice in the newly created
branches (“the external branches”), and moreover,
those involving Asp84β of the DP5 group occurred in
the differentiation of the DP2 and DP5 groups
(Fig. 4a and b; Supplementary Fig. 1b–e). Three
residues, Met11α, Gln31α, and Asp84β, are “non-
conserved” between HLA-DP5 and HLA-DP2
(Fig. 3j) and are also relevant to the distinct
peptide-binding specificities. Notably, Gln31α and
Asp84β form the negatively charged P1 pocket in
HLA-DP5. Thus, the crystal structure, together with
structural comparisons and evolutionary analyses,
revealed the specific differentiation of the P1 pocket
in the HLA-DP family.Discussion
In our previous study, we observed a statistically
significant association between HLA-DP5 and sus-
ceptibility to Japanese cedar pollinosis. We also
identified a dominant epitope, Cry j 1(208–227),
which was recognized in the context of HLA-DP5 by
CD4+ Th2 cells in many patients with Japanese
cedar pollinosis [22,23]. Therefore, we thought that
the HLA-DP5-associated susceptibility to Japanese
cedar pollinosis may be explained by HLA-DP5-me-
diated antigen presentation of the major Cry j 1
epitope to Th2 cells producing interleukin-4, an
essential cytokine for IgE production by antibody-
secreting plasma cells. Subsequently, the core
9-mer Cry j 1(214-KVTVAFNQF-222) peptide pre-
sented by HLA-DP5 was identified [22].
In the present study, we determined the crystal
structure of HLA-DP5 bound with this 9-mer Cry j 1
core peptide. In the structure, the peptide-binding
groove formed by the HLA-DP5α and HLA-DP5β
chains recognizes the KVTVAFNQF sequence
(Fig. 1), which corresponds exactly to the minimal
peptide previously proposed by in vitro experiments
[22]. Furthermore, we confirmed that HLA-DP5
exhibits the same Cry j 1-binding mode in solution,
3023Crystal Structure of the HLA-DP5•Cry j 1 Complex.through pull-down experiments using structure-
based mutations of Cry j 1(9-mer) (Fig. 2).
Previous four-digit allele-level typing studies of the
DPA1 and DPB1 alleles indicated that the residues
at positions 31(α), 56(β), and 85–87(β) are “non-
conserved” in the DP alleles (Table 2) [27]. In
addition, we compared the structures of the HLA-DP5·
Cry j 1 and HLA-DP2·pDRA complexes and identified
the characteristic positions that are responsible for the
distinct properties between HLA-DP5 and HLA-DP2,
with regard to the peptide-binding mode (Table 2). In
the present peptide-binding mode, the Lys residue at
theCry j 1(p1) position is a specific anchor residue, as it
forms a salt bridge with the negatively charged P1
pocket of HLA-DP5. The bottom of the p1 pocket
consists of the “non-conserved” residues at positions
31(α) and 84(β) and may accommodate different kinds
of side chains between HLA-DP5 and HLA-DP2
(Fig. 3a, b, and e). Similarly, Leu and Glu at positions
35(β) and 55(β), respectively, of HLA-DP5 alter the
shape of the p9 pocket, as compared to that of the P9
pocket involving Phe35(β) and Asp55(β) of HLA-DP2
(Fig. 3a, b, and h). Overall, the “non-conserved”
residues on the peptide-binding groove of HLA-DP5
generate its distinct pocket properties from those of
HLA-DP2. Therefore, the HLA-DP5·Cry j 1 complex
forms 10 hydrogen bonds between the groove and theFig. 5. Comparison of the peptide-binding motifs and the p
acid residues of the main anchor positions frequently detected
peptides bound to HLA-DP2 (b). (a and b) Calculations inclu
protein. (b) The chart constructed by using examples from
peptide-binding motifs and the pocket properties of HLA-DP5peptide (Fig. 2a), while these features are not observed
in the HLA-DP2·pDRA complex [25] (Fig. 2b).
Moreover, the Cry j 1(p5) position is pushed up by
Lys at position 69(β), in collaboration with Met at
position 11(α) of HLA-DP5, in the HLA-DP5·Cry j 1
complex (Fig. 3c, d, and f; Table 2). The region
around the p4 and p5 positions of the peptide is
frequently recognized by complementarity determin-
ing region 3 of the specific T cell receptor [28], and
the conformational features at the p5 position may
allow the peptide to escape from negative selection
in the thymus. In the HLA-DP2·pDRA crystal, the
complex adopted the auto-inhibited conformation for
beryllium (Be), by association with the N-terminal
Arg(p−2) of pDRA and the neighboring acidic pocket
of HLA-DP2 [25]. However, in the present HLA-DP5
structure, none of the peptide residues are inserted
in the pocket because the Lys at position 69(β) of
HLA-DP5 occupies the space (Fig. 3f and Table 2).
This is also relevant to the proposal by Dai et al. [25],
who noted that a Lys residue at the p4 position of an
HLA-DP2-binding peptide may not allow Be binding.
The evolutionary analysis revealed that the
Met11α, Gln31α, and Asp84β residues, which are
characteristic of HLA-DP5, are responsible for its
distinct peptide binding features. First, Gln31α and
Asp84β are critical for the specificity of the P1 pocketocket properties between HLA-DP5 and HLA-DP2. Amino
in the non-self-peptides bound to HLA-DP5 (a) and the self
ded only the longer peptide sequences from each source
a previous report [29]. (c) Relationships between the
and HLA-DP2.
3024 Crystal Structure of the HLA-DP5•Cry j 1 Complex.for the positively charged Lys(p1) residue (Fig. 3e).
Second, Met11α is involved in the mechanism
underlying the pushed-up position of the Phe(p6)
residue (Fig. 3d). This finding suggested that the
substitutions in the PBR could have been responsi-
ble for the diversification of the peptide-binding mode
within the DP5 group. Interestingly, Met11α of
HLA-DP5 and Ala11α of HLA-DP2 are coupled
with Lys69β and Glu69β, respectively (Table 2), to
form the haplotype-specific peptide-binding modes
described above. Furthermore, Leu35β of HLA-DP5
and Phe35β of HLA-DP2 are coupled with Glu55β
and Asp55β, respectively (Table 2), and these
interactions are important for the formation of the
different pocket sizes between HLA-DP5 and
HLA-DP2. These replacements occurred when the
two groups branched apart 20 million years ago.
Three other epitope peptides of Cry j 1/2 [Cry j 1
(61–75), Cry j 2 (81–95), and Cry j 2 (336–350)]
reportedly interact with HLA-DP5 [23]. Considering
that the negatively charged P1 pocket with Gln31α is
the major characteristic of the DP5 group, we
assigned a positively charged residue, K or R, in
the epitope peptides to the p1 position and then
examined if residues p2–p9 are compatible with the
properties of the corresponding pockets of HLA-DP5
(Supplementary Table 1a). Furthermore, we prelim-
inarily modeled the epitope peptides within the
peptide-binding groove, on the basis of the present
HLA-DP5·peptide complex structure (Supplemen-
tary Fig. 2a–c). Thus, we found that these peptides fit
well not only in the P1 pocket but also in the P6 and
P9 pockets and form 9–10 hydrogen bonds in total,
indicating that the assignment of K/R to p1 is
reasonable (Fig. 5a and Supplementary Table 1a).
Consequently, we concluded that the peptide-bind-
ing groove of the DP5 group can bind the epitope
peptides bearing p1Lys/Arg, with a certain allowance
for the other pockets.
On the other hand, 27 peptides, including Cry j 2
(185–193), reportedly associate with HLA-DP2
[23,29,30]. Considering the HLA-DP2·pDRA com-
plex structure, we assigned the aromatic residues, F
or Y, in these epitope peptides to the p1 and p6
positions and examined if their residues p2–p5/p7–
p9 are compatible with the peptide-binding groove of
HLA-DP2 (Supplementary Table 1b). Moreover, we
constructed several preliminary structural models
(Supplementary Fig. 2d and e). The p1 and p6 side
chains fit well in their corresponding pockets, and 4–
5 hydrogen bonds are formed in total. Interestingly,
Lys(p4) is most frequently observed for the DP2
epitope peptides (Fig. 5b and Supplementary
Table 1b) and fits nicely within the negatively
charged P4 pocket of HLA-DP2. Actually, the
epitope peptide with the putative optimal residues,
Phe(p1), Lys(p4), and Phe(p6), has been found [29],
whereas the other peptides have suboptimal side
chains at either p1/p6 or p4. In the case of theHLA-DP2·pDRA complex structure, the lack of
Lys(p4) in pDRA, which has Leu(p4) instead, is
compensated by the bound Be ion. It was previously
argued that the pDRA/Be-binding mode of HLA-DP2
is probably different from the others [25,31]. Overall,
the peptide-binding groove of the DP2 group can
bind these epitope peptides with a certain allowance.
For both the DP5 and DP2 groups, the properties
of the P6 pocket have been conserved to accom-
modate an aromatic side chain in the course of
evolution (Fig. 5c). In contrast, the DP5 and DP2
groups differentially acquired the negatively charged
pocket at the P1 and P4 positions, respectively
(Fig. 5c). It is likely that this evolutionary diversifica-
tion of the peptide-binding groove created the
specificities of the HLA-DP family members to
cover the present diversity of the epitope peptides.
The present crystal structure, together with the
structural comparisons and evolutionary analyses,
revealed the differentiation of the P1 pocket in the
HLA-DP family. These results provide the essential
structural basis for understanding the diversification
of the ligand-binding specificities in the HLA-DP
family, toward innovative pharmaceutical research
for patients with hay fever.Materials and Methods
Cloning, expression, and purification
The gene encoding the signal sequence and residues
1–181 of the HLA-DP5α chain was cloned into the
baculovirus transfer vector pFastBacDual (Life Technolo-
gies), as a fusion with the C-terminal tobacco etch virus
(TEV) protease cleavage site and a His tag. The gene
encoding residues 4–189 of the HLA-DP5β chain was
cloned into the resulting vector, as a fusion with the gp67
signal sequence followed by the nine-amino-acid residues
(KVTVAFNQF) of the Cry j 1 peptide and the linker
sequence (GGSLVPRGSGGGGS) at its N-terminus, as
well as the TEV protease cleavage site and FLAG tag at its
C-terminus. The baculovirus for the His-tagged HLA-DP5α
and FLAG-tagged Cry j 1–HLA-DP5β production was
created using the BAC-to-BAC Baculovirus Expression
System (Invitrogen). Spodoptera frugiperda cells (5 × 105
cells/ml), derived from expresSF+® Insect Cells (Protein
Sciences), were cultured in Sf-900™ III SFM (Life
Technologies) and infected with the viral stock at a
multiplicity of infection of 0.2. After 20 h at 27 °C in
suspension culture (125 rpm), the cells were pelleted and
resuspended in an equal volume of the medium and were
continuously cultured at 19 °C in suspension for 5 days.
The heterodimer HLA-DP5·Cry j 1(9-mer) was purified from
the culture supernatants by immobilized ANTI-FLAG® M2
Affinity Gel (Sigma) and then the C-terminal tag of the
heterodimer in the eluate was removed by an overnight
treatment with TEV protease at 4 °C. Seven residues
(GSSGSSG) from the tag remain at the C-terminus
because of the location of the TEV cleavage site. The
heterodimer was further purified by size-exclusion
3025Crystal Structure of the HLA-DP5•Cry j 1 Complex.chromatography (Superdex 200 HR 10/30; GE Healthcare)
and eluted with 20 mM Tris–HCl buffer (pH 8.0) containing
150 mM NaCl. The appropriate fractions were collected
according to the SDS-PAGE analysis.Analytical ultracentrifugation
All of the analytical ultracentrifugation experiments were
performed at 4 °C, using an An-50 Ti rotor and a Beckman
Optima XL-I analytical ultracentrifuge. Absorbance scans
were recorded at 280 nm. The sample buffer was 20 mM
Tris–HCl, pH 8.0, containing 150 mM NaCl. The solvent
density and the protein partial specific volume (υ ) were
estimated using the program SEDNTERP†. The sedimen-
tation coefficient was determined from sedimentation
velocity experiments, performed at a rotor speed of
40,000 rpm. The concentrations of the protein samples
were 0.32 and 0.16 mg/ml. The data were analyzed with
the program SEDFIT [32]. For the sedimentation equilib-
rium experiments, protein samples at three different
concentrations (0.40, 0.27, and 0.13 mg/ml) were centri-
fuged at rotor speeds of 6000, 7500, 9000, 10,500, and
12,000 rpm until the sedimentation–diffusion equilibrium
was reached (16 h). The equilibrium data were fitted using
the manufacturer's software (Beckman XL-A/XL-I Data
Analysis Software ver. 6.03).Crystallization and X-ray data collection
The preliminary crystals of the HLA-DP5·Cry j 1(9-mer)
complex were obtained by initial crystallization screening,
using the 96-well sitting-drop vapor diffusion method (Hamp-
ton Research). The crystals of the HLA-DP5·Cry j 1(9-mer)
complex used for structure determination were obtained by
the sitting-drop vapor diffusion method, by mixing the protein
solution (0.7 mg/ml) with an equal volume of the reservoir
solution [24% (w/v) polyethylene glycol 3350 and 0.2 M
ammonium nitrate] and incubating the mixture at 20 °C.
Plate-like crystals grew to average dimensions of
0.5 mm × 0.2 mm × 0.01 mm within 2 weeks. A single
crystal of HLA-DP5·Cry j 1(9-mer) was coated with its
reservoir solution, containing 22.5%polyethylene glycol 400
as cryoprotectant, and was flash-cooled in liquid nitrogen.
The native diffraction data of HLA-DP5·Cry j 1(9-mer) were
collected at −173 °C at a single wavelength at X06SA,
Swiss Light Source, and were recorded on a MARmosaic
225CCDdetector (Rayonix, USA). All of theHLA-DP5·Cry j
1(9-mer) diffraction data were processed with the XDS
program [33]. The crystallographic data and the data
collection statistics of HLA-DP5·Cry j 1(9-mer) are provided
in Table 1.Structure determination and refinement
We solved the structure of the HLA-DP5·Cry j 1(9-mer)
heterodimer by molecular replacement with PHASER [34],
using the reported HLA-DP2 structure (PDB accession
code: 3LQZ), with pDRA omitted, as a search model. This
solution was subjected to one round of simulated
annealing refinement in PHENIX [35]. The initial maps
showed additional density in the peptide-binding groove,
which indicated the binding site for Cry j 1(9-mer). TheHLA-DP5·Cry j 1(9-mer) model was subsequently com-
pleted by manual rebuilding in Coot [36] and rigid-body
refinement in PHENIX, with a single B-factor per domain,
using local non-crystallographic symmetry restraints
throughout. The last round of refinement was performed
without non-crystallographic symmetry. There are four
HLA-DP5·Cry j 1(9-mer) complexes in the asymmetric
unit. Refinement statistics are provided in Table 1. The
programs PROCHECK [37] and MolProbity [38] were used
to assess the geometry of the final model. Ramachandran
statistics are as follows [favored/disallowed (%)]:
HLA-DP5·Cry j 1(9-mer), 98/0.1. Alignments were calcu-
lated using CLUSTAL W [39]. Figures were produced
using PyMOL‡.In vitro protein binding assay
The DNA fragments encoding the full-length ectodomain
of HLA-DP5α (residues 1–181) and that of HLA-DP5β
(residues 4–189) as an N-terminal fusion with the nine-
amino-acid residue Cry j 1 peptide (KVTVAFNQF) were
cloned into the TA vector pCR2.1TOPO (Invitrogen).
HLA-DP5α and HLA-DP5β are fusion proteins containing
C-terminal histidine and FLAG tags, respectively, following
the TEV protease cleavage site. The Kp1E, Tp3Y, Np7Q,
Qp8E, and Fp9A mutants of Cry j 1(9-mer) were prepared
by site-directed mutagenesis, using a QuikChange Site-
Directed Mutagenesis kit (Stratagene). These variants
were synthesized using the small scale dialysis mode of
the Escherichia coli cell-free reaction [40,41] in the
presence of disulfide isomerase and GSH/GSSG. Equal
amounts of HLA-DP5 in complex with Cry j 1(WT) and Cry j
1(Mutants) were incubated with Ni-NTA agarose (Qiagen)
beads. The beads were washed 10 times with washing
buffer [20 mM Tris–HCl buffer (pH 8.0), containing
150 mM NaCl and 20 mM imidazole]. The bound proteins
were eluted with 20 mM Tris–HCl buffer (pH 8.0), contain-
ing 150 mM NaCl and 500 mM imidazole, resolved by
SDS-PAGE and stained by Coomassie Brilliant Blue.
Simultaneously, equal amounts of these variants were
incubated with ANTI-FLAG® M2 Affinity Gel (Sigma)
beads. The beads were washed five times with washing
buffer [20 mM Tris–HCl buffer (pH 8.0), containing
150 mM NaCl and 1 mM ethylenediaminetetraacetic
acid]. The bound proteins were eluted with 20 mM Tris–
HCl buffer (pH 8.0), containing 150 mM NaCl, 1 mM
ethylenediaminetetraacetic acid, and 0.1 mg/ml 3×
FLAG® Peptide (Sigma), and the fractions were analyzed
by SDS-PAGE and immunoblotted with an ANTI-FLAG®
M2 Monoclonal Antibody (Sigma). Immunoblotting images
were obtained using a Luminescent Image Analyzer
(LAS-4000; GE Healthcare).Phylogenic analysis
The NJ tree [42] of synonymous substitutions was
constructed by using a program implemented in MEGA5
[43]. On the NJ tree, amino acid substitutions within the
PBRs of the DPα and DPβ chains were manually placed
parsimoniously. For DPA1, DRA1 sequences were used
as outgroups, but for DPB1, outgroup sequences were not
used. Instead, the root was placed on an inter-nodal
branch of the DP2 and DP5 groups.
3026 Crystal Structure of the HLA-DP5•Cry j 1 Complex.Accession number
The atomic coordinates and structure factors of the
HLA-DP5·Cry j 1(9-mer) complex have been deposited in
the PDB, with the accession code 3WEX.Acknowledgements
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